Gilead Sciences Signs Voluntary Licensing Pacts for HIV Medication Lenacapavir

Gilead Sciences, a US biopharmaceuticals company, has signed voluntary licensing pacts with six drug makers to sell and produce an anti-HIV medication called lenacapavir, primarily for low- and lower-middle-income countries. The non-exclusive, royalty-free agreements will enable Dr Reddy's Laboratories, Emcure, and Hetero in India, Eva Pharma in Egypt, Ferozsons Laboratories in Pakistan, and Mylan in the US to manufacture and supply lenacapavir to 120 resource-limited countries. Public health advocates expect generic versions of lenacapavir to cost significantly lower than Gilead's reported price of $42,250.

Key Takeaways:

• Gilead Sciences has signed voluntary licensing pacts with six drug makers to sell and produce lenacapavir, an anti-HIV medication, primarily for low- and lower-middle-income countries.
• The agreements will enable Dr Reddy's Laboratories, Emcure, and Hetero in India, Eva Pharma in Egypt, Ferozsons Laboratories in Pakistan, and Mylan in the US to manufacture and supply lenacapavir to 120 resource-limited countries.
• Public health advocates expect generic versions of lenacapavir to cost significantly lower than Gilead's reported price of $42,250.
• Lenacapavir has demonstrated superior efficacy over standard oral preventive medicines in clinical trials.
• UNAIDS has stated that lenacapavir "provides hope of accelerating efforts to end AIDS" but only if Gilead ensures broad access to the medicine.
• Gilead's agreements with the six companies advance its strategy to enable broad, sustainable access to lenacapavir for pre-exposure prophylaxis globally.
• Gilead's CEO, Daniel O'Day, emphasized the "urgency" of working with high-volume generic manufacturers to ensure a rapid transition to voluntary license partners after lenacapavir is approved for pre-exposure prophylaxis.

Statistics:

• 120 countries will have access to lenacapavir under the voluntary licensing agreements.
• Gilead's reported price of lenacapavir is $42,250.
• Clinical trials have demonstrated lenacapavir's superior efficacy over standard oral preventive medicines.
• 6 drug makers have signed voluntary licensing pacts with Gilead Sciences.

Sources:

• Gilead Sciences, announced on Wednesday
• Dr Reddy's Laboratories, Emcure, and Hetero in India, Eva Pharma in Egypt, Ferozsons Laboratories in Pakistan, and Mylan in the US
• UNAIDS, a UN agency